Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.46
CYTX's Cash to Debt is ranked higher than
52% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. CYTX: 0.46 )
CYTX' s 10-Year Cash to Debt Range
Min: 0.3   Max: N/A
Current: 0.46

Equity to Asset -0.63
CYTX's Equity to Asset is ranked lower than
52% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CYTX: -0.63 )
CYTX' s 10-Year Equity to Asset Range
Min: -0.83   Max: 0.94
Current: -0.63

-0.83
0.94
F-Score: 2
Z-Score: -16.48
M-Score: -5.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -515.80
CYTX's Operating margin (%) is ranked higher than
60% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. CYTX: -515.80 )
CYTX' s 10-Year Operating margin (%) Range
Min: -3958.33   Max: -68.58
Current: -515.8

-3958.33
-68.58
Net-margin (%) -575.00
CYTX's Net-margin (%) is ranked higher than
60% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. CYTX: -575.00 )
CYTX' s 10-Year Net-margin (%) Range
Min: -3620.2   Max: -30.65
Current: -575

-3620.2
-30.65
ROA (%) -131.70
CYTX's ROA (%) is ranked higher than
51% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. CYTX: -131.70 )
CYTX' s 10-Year ROA (%) Range
Min: -138.62   Max: -7.8
Current: -131.7

-138.62
-7.8
ROC (Joel Greenblatt) (%) -2593.30
CYTX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. CYTX: -2593.30 )
CYTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2460.14   Max: -173.31
Current: -2593.3

-2460.14
-173.31
Revenue Growth (3Y)(%) -22.00
CYTX's Revenue Growth (3Y)(%) is ranked higher than
66% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. CYTX: -22.00 )
CYTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 97.2
Current: -22

0
97.2
EBITDA Growth (3Y)(%) -9.50
CYTX's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CYTX: -9.50 )
CYTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27.3   Max: 37.5
Current: -9.5

-27.3
37.5
EPS Growth (3Y)(%) -7.70
CYTX's EPS Growth (3Y)(%) is ranked higher than
75% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. CYTX: -7.70 )
CYTX' s 10-Year EPS Growth (3Y)(%) Range
Min: -41.5   Max: 102.7
Current: -7.7

-41.5
102.7
» CYTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CYTX Guru Trades in Q1 2014

Paul Tudor Jones 14,433 sh (+30.90%)
Jim Simons Sold Out
» More
Q2 2014

CYTX Guru Trades in Q2 2014

Paul Tudor Jones 14,633 sh (+1.39%)
» More
Q3 2014

CYTX Guru Trades in Q3 2014

Jim Simons 475,131 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2014

CYTX Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 6.90
CYTX's P/S is ranked higher than
79% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. CYTX: 6.90 )
CYTX' s 10-Year P/S Range
Min: 3.7   Max: 43.94
Current: 6.9

3.7
43.94
EV-to-EBIT -2.24
CYTX's EV-to-EBIT is ranked higher than
84% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CYTX: -2.24 )
CYTX' s 10-Year EV-to-EBIT Range
Min: -16   Max: -1.3
Current: -2.24

-16
-1.3
Current Ratio 1.06
CYTX's Current Ratio is ranked higher than
52% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CYTX: 1.06 )
CYTX' s 10-Year Current Ratio Range
Min: 1.01   Max: 26.46
Current: 1.06

1.01
26.46
Quick Ratio 0.82
CYTX's Quick Ratio is ranked higher than
52% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CYTX: 0.82 )
CYTX' s 10-Year Quick Ratio Range
Min: 0.66   Max: 24.95
Current: 0.82

0.66
24.95
Days Inventory 542.78
CYTX's Days Inventory is ranked higher than
77% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CYTX: 542.78 )
CYTX' s 10-Year Days Inventory Range
Min: 36.86   Max: 529.06
Current: 542.78

36.86
529.06
Days Sales Outstanding 30.20
CYTX's Days Sales Outstanding is ranked higher than
93% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. CYTX: 30.20 )
CYTX' s 10-Year Days Sales Outstanding Range
Min: 4.15   Max: 124.26
Current: 30.2

4.15
124.26

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.60
CYTX's Price/Median PS Value is ranked higher than
94% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. CYTX: 0.60 )
CYTX' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 3.29
Current: 0.6

0.41
3.29
Earnings Yield (Greenblatt) -44.60
CYTX's Earnings Yield (Greenblatt) is ranked lower than
62% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. CYTX: -44.60 )
CYTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -56.3   Max: 0
Current: -44.6

-56.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XMPA.Germany,
Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celution System, which extracts the naturally occurring ADRCs from a patient's own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue banking lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for CYTX

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 
5-year lows: Fuel Systems Solutions Inc, Dawson Geophysical Co, Forest Oil Corp, and Cytori Therapeu Sep 08 2014 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: SSP, HPOL, CYTX, AGYS, VRX, TPI Mar 19 2012 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 09 2010 
Cytori Therapeutics Inc (CYTX) CFO Mark E Saad buys 6,000 Shares May 21 2010 
cooldecency99 note on CYTX May 01 2010 
creiter note on CYTX Jan 03 2010 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 10 2009 
Cytori Reports 2nd Quarter 2009 Financial Results Aug 10 2009 

More From Other Websites
CYTORI THERAPEUTICS, INC. Financials May 20 2015
10-Q for Cytori Therapeutics, Inc. May 13 2015
Cytori reports 1Q loss May 11 2015
Cytori reports 1Q loss May 11 2015
Cytori Reports First Quarter 2015 Business and Financial Results May 11 2015
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 11 2015
Cytori Reports First Quarter 2015 Business and Financial Results May 11 2015
Q1 2015 Cytori Therapeutics Inc Earnings Release - After Market Close May 11 2015
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... May 05 2015
Cytori Prices Registered Direct Offering Providing for up to $25 million in Equity Financing May 05 2015
Cytori Prices Registered Direct Offering Providing for up to $25 million in Equity Financing May 05 2015
10-K for Cytori Therapeutics, Inc. May 04 2015
Cytori First Quarter Financial Results Update Apr 30 2015
Cytori First Quarter Financial Results Update Apr 30 2015
Cytori Provides Twelve Month Data Update on Scleradec-I Trial Apr 23 2015
Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds... Apr 23 2015
Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds... Apr 23 2015
The Zacks Analyst Blog Highlights: Pfizer, Pharmacyclics, Geron, Anthera Pharmaceuticals and Cytori... Apr 16 2015
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 13 2015
Cytori Provides Twelve Month Data Update on Scleradec-I Trial Apr 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK